
Virtuix Wins US Air Force Contract; Expands into AI Therapy
Virtuix Holdings Inc. announced significant business developments, including its selection by the U.S. Air Force for Phase I funding under the AFWERX SBIR program to develop its Virtual Terrain Walk (VTW) platform for military mission planning. Additionally, the company expanded into AI-assisted neurodivergent therapy through a collaboration with Rutgers University, which deployed the Omni One platform for research. Concurrently, Virtuix consummated an exchange of outstanding secured convertible promissory notes for a new Pre-Paid Purchase in the principal amount of $3,471,923.00, bearing 6% annual interest.
Key Highlights
- US Air Force selected Virtuix for Virtual Terrain Walk (VTW) platform.
- Secured Phase I funding under AFWERX SBIR program for VTW development.
- Rutgers University deployed Omni One for AI-assisted neurodivergent therapy research.
- Global ASD treatment market projected to grow from $9.2B (2026) to $18B (2034).
- Exchanged prior notes for new Pre-Paid Purchase of $3,471,923.00.
- Pre-Paid Purchase bears 6% annual interest, compounded daily.
- Investor (Streeterville) limited to 9.99% beneficial ownership of common stock.
Price Impact
More from VTIX
Virtuix Holdings Amends Warrants, Exercise Price Reduced to $3.00
Virtuix FY26 Revenue +18% to $4.3M; Gross Margin 25%; Launches Omni One for Quest
Virtuix Holdings Completes Nasdaq Direct Listing, Secures $8M Initial Equity Advance